Determinants of Psychological Well-being in Axial Spondyloarthritis: an Analysis Based on Linked Claims and Patient-reported Survey Data
Overview
Authors
Affiliations
Objectives: The aim of this study was to assess the psychological well-being and to analyse factors associated with depressive symptoms in axial spondyloarthritis (axSpA).
Methods: A stratified random sample of subjects with a diagnosis of axSpA (International Classification of Diseases, Tenth Revision, German Modification M45) was drawn from health insurance data in Germany. These persons received a postal questionnaire on disease-related, psychological and lifestyle factors as well as socioeconomic status. Additional information to verify the axSpA diagnosis was also collected. The psychological well-being was assessed by means of the 5-item WHO Well-Being Index (WHO-5), which is considered a screening tool for depression. The following established cut-offs on the WHO-5 were applied: >50: good well-being, no depressive symptoms; 29-50: mild depressive symptoms; ≤28: moderate-to-severe depressive symptoms. Information on comorbidities, drug prescriptions and non-pharmacological treatment was retrieved from claims data and linked to the questionnaire data.
Results: A total of 1736 persons with a confirmed axSpA diagnosis were included. Using the cut-offs on the WHO-5, 533 persons (31%) were found to have moderate-to-severe depressive symptoms, 479 (28%) had mild depressive symptoms and 724 (42%) had a good well-being. Multivariable logistic regression revealed that higher disease activity, higher level of functional impairment, lower income, self-reported stress and lack of exercise, and younger age represent factors associated with moderate-to-severe depressive symptoms.
Conclusions: The prevalence of depressive symptoms in axSpA subjects is high and associated with disease-related parameters, socioeconomic status and lifestyle factors. These findings highlight the need for the careful evaluation of depressive symptoms as a part of the management strategy for axSpA.
Vaupel K, Kiefer D, Ramiro S, Kiltz U, van Lankveld W, Hammel L J Patient Rep Outcomes. 2025; 9(1):5.
PMID: 39786655 PMC: 11718023. DOI: 10.1186/s41687-024-00828-3.
Rahman P, Garrido-Cumbrera M, Rohekar S, Mallinson M, Karam E, Jovaisas A Musculoskeletal Care. 2024; 22(4):e70010.
PMID: 39658831 PMC: 11632139. DOI: 10.1002/msc.70010.
Callhoff J, Berger K, Albrecht K, Strangfeld A RMD Open. 2024; 10(4).
PMID: 39448206 PMC: 11499824. DOI: 10.1136/rmdopen-2024-004808.
Berr K, Ziehfreund S, Welcker M, Biedermann T, Zink A Sci Rep. 2024; 14(1):19977.
PMID: 39198468 PMC: 11358462. DOI: 10.1038/s41598-024-70420-8.
Garrido-Cumbrera M, Navarro-Compan V, Poddubnyy D, Sommerfleck F, Makri S, Correa-Fernandez J RMD Open. 2024; 10(2).
PMID: 38866592 PMC: 11177769. DOI: 10.1136/rmdopen-2024-004218.